While routine testing for hormone receptor status prior to treatment initiation is uncommon, in a recent meta-analysis of five East African countries, 55% of women with breast cancer were estrogen receptor (ER) positive compared to 72% in the United States [36]. The gene discussed is ESR1; the disease is breast carcinoma.